2014
DOI: 10.1007/978-3-319-09665-0_13
|View full text |Cite
|
Sign up to set email alerts
|

High-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic Consequences

Abstract: High-density lipoprotein (HDL) has attracted interest as a therapeutic target in cardiovascular diseases in recent years. Although many functional mechanisms of the vascular protective effects of HDL have been identified, increasing the HDL plasma level has not been successful in all patient cohorts with increased cardiovascular risk. The composition of the HDL particle is very complex and includes diverse lipids and proteins that can be modified in disease conditions. In patients with chronic kidney disease (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 152 publications
0
4
0
1
Order By: Relevance
“…It was also reported that a higher HDL-C level was not associated with a reduced mortality risk and CAD severity in patients with reduced kidney function [23]. Furthermore, patients with CKD were reported to show changes in the composition of and decreased protective function of HDL-C [24]. The vascular effects of HDL-C in patients with DKD might differ from those in normal patients.…”
Section: Discussionmentioning
confidence: 99%
“…It was also reported that a higher HDL-C level was not associated with a reduced mortality risk and CAD severity in patients with reduced kidney function [23]. Furthermore, patients with CKD were reported to show changes in the composition of and decreased protective function of HDL-C [24]. The vascular effects of HDL-C in patients with DKD might differ from those in normal patients.…”
Section: Discussionmentioning
confidence: 99%
“…Increase in cholesteryl ester transfer protein (CETP) and decreased lecithin-cholesterol acyltransferase (LCAT) activity contributes to decreased HDL-cholesterol levels. (Schuchardt et al, 2015). Beyond reduced HDL cholesterol levels, the HDL in CKD is less effective in its anti-oxidative and anti-inflammatory functions.…”
Section: Hyperlipidemiamentioning
confidence: 99%
“…46 Reduced activity of lecithincholesterol acyltransferase and elevated protein transfer cholesterol esterol (CETP) event lead to reduced levels of HDL cholesterol. [47] Statins are the frequently used lipid-lowering drugs are listed in (Table 2).…”
Section: Cardiovascular Riskmentioning
confidence: 99%